Study Summary
Following pre-treatment with cyclophosphamide and/or fludarabine, MAGE-A4-specific TCR gene transduced T lymphocytes are transferred to the patients with MAGE-A4-expressing solid tumors.
Want to learn more about this trial?
Request More InfoInterventions
TBI-1201DRUG
TBI-1201(5\*10\^8 or 5\*10\^9) is administered.
CyclophosphamideDRUG
Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1201
FludarabineDRUG
Fludarabine (20mg/m2 x 5 days Intravenous(IV)) is administered as pre-treatment medication of TBI-1201 in combination with cyclophosphamide.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Mie University Hospital | Tsu | Mie-ken | Japan |